Sutro Biopharma (STRO) Operating Expenses (2017 - 2026)

Sutro Biopharma has reported Operating Expenses for 9 years, with the latest figure at $49.7 million in Q4 2025.

• Quarterly Operating Expenses fell 37.93% year-over-year to $49.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $260.9 million (down 13.19% YoY) and the FY2025 annual result came in at $260.9 million, down 13.19% from the prior year.
• Operating Expenses retreated to $49.7 million in Q4 2025 per STRO's latest filing, from $58.2 million in the prior quarter.
• Over five years, Operating Expenses peaked at $85.9 million in Q1 2025 and troughed at $33.7 million in Q1 2021.
• A 5-year average of $58.1 million and a median of $57.2 million in 2022 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2021 and 2025: Operating Expenses surged 51.87% in 2021, then slumped 37.93% in 2025.
• Over 5 years, Operating Expenses stood at $45.7 million in 2021, then climbed by 26.62% to $57.9 million in 2022, then advanced by 21.98% to $70.6 million in 2023, then gained by 13.46% to $80.1 million in 2024, then tumbled by 37.93% to $49.7 million in 2025.
• According to Business Quant data, Operating Expenses over the past three periods registered $49.7 million, $58.2 million, and $67.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.